Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (NCT04464980)
NIDA-CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
🩺 Plain-English Summary (8th-Grade Level)
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Who can join: Review the eligibility criteria below.
Location: University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST) — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST) — Little Rock, Arkansas
- Tarzana Treatment Centers, Inc. — Tarzana, California
- Liberation Programs, Inc. — Bridgeport, Connecticut
- Operation PAR — Clearwater, Florida
- Gateway Community Services — Jacksonville, Florida
- Aspire Health Partners — Orlando, Florida
- Mountain Manor / Maryland Treatment Centers — Baltimore, Maryland
- McLean Hospital — Belmont, Massachusetts
- Stanley Street Treatment and Resources, Inc. — Fall River, Massachusetts
- Square Medical Group, LLC — Newton, Massachusetts
- Gibson Center for Behavioral Change — Cape Girardeau, Missouri
- Dartmouth Hitchcock - ATP — Lebanon, New Hampshire
- University of New Mexico Addiction and Substance Abuse Program — Albuquerque, New Mexico
- Bellevue Hospital Center — New York, New York
- Adapt Integrated Health Care — Roseburg, Oregon
- Adapt Integrated Health Care — Winston, Oregon
- Center for Psychiatric and Chemical Dependency Services (CPCDS) — Pittsburgh, Pennsylvania
- Internal Medicine Recovery Engagement Program (IM-REP) — Pittsburgh, Pennsylvania
- Shoreline Behavioral Health Services — Conway, South Carolina
- Huntsman Mental Health Institute / University of Utah — Salt Lake City, Utah
- Chestnut Ridge Center — Morgantown, West Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Opioid Use Disorder (OUD)
- Mindfulness Texting for Medication Adherence and Chronic Pain Management — Albuquerque, New Mexico
- Mapping Ibogaine Neural Dynamics in Opioid Use Disorder — Irvine, California
- MethaLoad Dose-Finding Study — Philadelphia, Pennsylvania
- Adjunctive Cannabidiol for Recovery From Opioid Study — New York, New York
- Opioid Adherence and Support Through Innovative Texting Strategies — Albuquerque, New Mexico
Explore by condition: All Opioid Use Disorder (OUD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.